HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA. TRUMENBA® (Meningococcal Group B Vaccine) Suspension for intramuscular injection Initial U.S. Approval: 2014 RECENT MAJOR CHANGESINDICATIONS AND USAGETrumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age. (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSSuspension for intramuscular injection in 0.5 mL single-dose prefilled syringe. (3) CONTRAINDICATIONSSevere allergic reaction (e.g., anaphylaxis) to any component of Trumenba. (4) WARNINGS AND PRECAUTIONSSyncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting. (5.4) ADVERSE REACTIONSThe most common solicited adverse reactions in adolescents and young adults were pain at the injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or http://vaers.hhs.gov. USE IN SPECIFIC POPULATIONSPediatric Use: Safety and effectiveness have not been established in children <10 years of age. In a clinical study, 90% of infants <12 months of age who were vaccinated with a reduced dosage formulation had fever. (8.4) See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2021 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
TRUMENBA®Highlights (Meningococcal Group B Vaccine)
Resources
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at(800) 438-1985.
(800)-332-1088.